July 2023

Stocks rose Friday with the Dow Jones Industrial Average and S&P 500 closing out their third winning weeks in a row as a measure of inflation closely watched by the Federal Reserve came in at its lowest in nearly two years. The Dow jumped 176.57 points, or 0.50per cent, to 35,459.29. The S&P 500 added […]

Dr Shane Oliver, Head of Investment Strategy & Chief Economist at AMP, discusses developments in investment markets over the past week, economic activity trackers, major global economic events and Australia economic events. Investment markets and key developments over the past week Global shares were mixed over the last week being buoyed by increasing confidence that

Michael Shirley – Managing Director & CEO – Veris (ASX:VRS) is a leading provider of spatial data services in Australia. Their expertise spans data collection and capture, using all types of sensors, as well as data processing, hosting, management, modelling, analysis, visualisation and sharing.

Iain Dunstan – CEO & Managing Director – Gratifii (ASX:GTI) provides a full-service solution that transforms how brands manage and deliver loyalty and rewards, offering a comprehensive platform combining technology, content, and services for effective loyalty programs.

Victor Tsaccounis CEO & Nick Fitzgerald CFO – Hubify (ASX:HFY) provides Australian businesses with a one-stop shop for their telecommunication and IT needs.

Mark Miocevich – Managing Director – VEEM (ASX:VEE) is a designer and manufacturer of disruptive, high-technology marine propulsion and stabilisation systems for the global luxury motor yacht, fast ferry, commercial workboat and defence industries.

Australian retail sales experienced a 0.8% decline last month, as reported by the Australian Bureau of Statistics. This result came as a surprise to markets, which had anticipated a steady performance for June following a robust 0.7% gain in May. At noon, the S&P/ASX 200 is 0.8 per cent lower at 7,396. The SPI futures

First Patient Dosed in Chemotherapy-Free Triple Combination Phase II Trial Targeting Soft Tissue Sarcoma Immutep (ASX:IMM; NASDAQ:IMMP) announced that the first patient has been dosed in the Chemotherapy-free Combination Phase II Trial Targeting Sarcoma, a disease in which malignant (cancer) cells form in the soft tissues of the body. In response, Immutep CSO, Frédéric Triebe

The bloom has faded from the boom in energy company earnings as world prices and demand sag compared to the invasion-stimulated highs a year ago. Oil giants, Shell and TotalEnergies, reported sharp falls in June quarter profits, and expectations are that giants like BP, Chevron, and Exxon Mobil will repeat the news in the next